-
Roche’s Ocrevus Approved by China’s NMPA for Multiple Sclerosis Treatment
•
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its selective immunosuppressant Ocrevus (ocrelizumab). The drug is approved for the treatment of adults with recurrent multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting multiple sclerosis, and…
-
Merck KGaA Partners with Roche to Commercialize Tepmetko in China
•
Germany-based pharmaceutical giant Merck KGaA (ETR: MRK) has entered into a partnership with Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) to commercialize its lung cancer targeted drug Tepmetko (tepotinib) in mainland China. This collaboration aims to leverage the strengths of both companies to bring Tepmetko to more patients in need.…
-
Oxford BioTherapeutics Partners with Roche on Cancer Therapeutics Discovery
•
On March 19, 2025, Oxford BioTherapeutics announced a multiyear collaboration with Roche (SWX: ROG, OTCMKTS: RHHBY) to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer. This partnership leverages Oxford BioTherapeutics’ innovative discovery platform to identify and validate new targets for cancer therapies. OGAP-Verify Discovery PlatformOxford BioTherapeutics’ recently…
-
Roche’s Itovebi Approved in China for PIK3CA-Mutated Breast Cancer
•
Itovebi (inavolisib), a best-in-class PI3Kα inhibitor from Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY), has received approval from China’s National Medical Products Administration (NMPA). The drug is indicated for use in combination with palbociclib and fulvestrant in adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative,…
-
Roche and Zealand Pharma Collaborate to Develop Petrelintide for Weight Management
•
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced a strategic exclusive collaboration and licensing agreement with Denmark-based Zealand Pharma (CPH: ZEAL). The partnership aims to develop and commercialize petrelintide, Zealand Pharma’s amylin analog, both as a standalone therapy and in a fixed-dose combination with Roche’s lead incretin asset CT-388.…
-
Roche Launches Genentech Innovation Center in Boston to Accelerate Drug Development
•
Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston. This new facility aims to strengthen longstanding partnerships in disease biology, engineering, and artificial intelligence/machine learning. CVRM Hub and AI IntegrationThe center will serve as Roche’s…
-
Roche and JD Healthcare Collaborate on Influenza Prevention with Xofluza (Baloxavir Marboxil)
•
Swiss giant Roche’s (SWX: ROG, OTCMKTS: RHHBY) China unit has entered into a collaboration agreement with JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD). This partnership aims to enhance the prevention and control of influenza in China through the innovative “medicine+Internet medicine” model, making Xofluza (baloxavir marboxil)…
-
Roche’s Gazyva Receives FDA Review Acceptance for Lupus Nephritis Treatment
•
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that the US Food and Drug Administration ()FDA has accepted for review its supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) for the treatment of lupus nephritis. The FDA is expected to make its decision by October 2025. The filing…
-
Baheal Pharmaceutical Gains Exclusive Rights to Roche’s MabThera in China
•
China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015) last month reached an accord with Roche (SWX: ROG, OTCMKTS: RHHBY), securing exclusive market promotion rights to the Swiss giant’s MabThera (rituximab) in mainland China. Drug ProfileMabThera, the world’s first anti-CD20 monoclonal antibody (mAb), is used to treat Hodgkin…
-
Genentech’s TNKase Approved by FDA for Acute Ischemic Stroke Treatment
•
Genentech, a subsidiary of Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY), announced that its thrombolytic agent TNKase (tenecteplase) has been approved by the US Food and Drug Administration (FDA) for the treatment of acute ischemic stroke (AIS) in adults. Drug ProfileTNKase, a tissue plasminogen activator, is administered as a single…
-
Roche Unveils Sequencing by Expansion (SBX) Technology for Next-Generation Sequencing
•
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the presentation of its proprietary sequencing by expansion (SBX) technology, marking a significant advancement in next-generation sequencing (NGS). Technology OverviewSBX integrates innovative sensor modules to provide ultra-fast and high-throughput sequencing solutions. The technology is designed with broad flexibility and scalability, making…
-
Roche’s Tecentriq Wins Japan Approval for Alveolar Soft Part Sarcoma
•
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) and its Japanese partner Chugai Pharmaceutical Co., Ltd. (TYO: 4519) announced that the Ministry of Health, Labour and Welfare of Japan has approved Tecentriq (atezolizumab) for the treatment of unresectable alveolar soft part sarcoma. This marks the first approval of an immune…
-
Roche’s cobas liat STI Assay Panels Gain FDA Approval and CLIA Waiver
•
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced receiving approval from the US Food and Drug Administration (FDA) and a Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver for its cobas liat sexually transmitted infection (STI) multiplex assay panels. This marks a significant advancement in rapid diagnostic capabilities…
-
Roche’s VENTANA Kappa and Lambda Dual ISH Test Gains FDA Clearance
•
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that it has received marketing clearance from the United States Food and Drug Administration (FDA) for its highly-sensitive in-situ hybridisation (ISH) test, the VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail. This follows the test’s CE Mark approval in…
-
Roche Gains FDA 510(k) Clearance for Roche Digital Pathology Dx with VENTANA DP 600
•
Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced an additional 510(k) clearance from the US FDA for its Roche Digital Pathology Dx, a whole slide imaging system that now includes the VENTANA DP 600 slide scanner. This clearance expands the capabilities of Roche’s digital pathology solutions, enhancing the diagnostic…
-
Roche’s VENTANA CLDN18 Assay Receives EU Approval, Enhances Targeted Therapy Options for Gastric Cancer
•
Roche (SWX: ROG; OTCMKTS: RHHBY) has secured CE Mark approval in the European Union for its VENTANA CLDN18 (43-14A) RxDx Assay, marking a pivotal advancement in the treatment landscape for gastric cancer. This immunohistochemistry (IHC) companion diagnostic (CDx) test is the first to determine CLDN18 protein expression in tumors of…
-
Regor Therapeutics Strikes Deal with Genentech for CDK Inhibitors, Fetching USD 850 Million Upfront
•
Regor Therapeutics Group, a US-based biotech with significant ties to China, has entered into a licensing agreement with Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG; OTCMKTS: RHHBY) . Under the agreement, Genentech will acquire the rights to develop, manufacture, and commercialize Regor’s next-generation CDK inhibitors, including the…
-
Roche’s Xofluza Receives FDA Approval for Reducing Influenza Transmission in Phase III Study
•
Roche (SWX: ROG; OTCMKTS: RHHBY) has announced that its antiviral drug Xofluza (baloxavir marboxil) has received approval from the US Food and Drug Administration (FDA) based on positive results from the Phase III CENTERSTONE study. The study demonstrated that a single dose of Xofluza significantly reduced the transmission of influenza…
-
Roche’s Tecentriq Hybreza Becomes First Subcutaneous Anti-PD-(L)1 Immunotherapy in the US
•
Roche (SWX: ROG; OTCMKTS: RHHBY) , a leading Swiss pharmaceutical company, has secured US Food and Drug Administration (FDA) approval for its subcutaneous formulation of the programmed death-ligand 1 (PD-L1) inhibitor, Tecentriq Hybreza (atezolizumab, hyaluronidase). This new formulation has been approved for all 12 adult indications of intravenous Tecentriq, covering…
-
Roche’s Ocrevus Zunovo Receives FDA Nod as First Twice-Yearly MS Treatment
•
Roche Group (SWX: ROG; OTCMKTS: RHHBY) , a Swiss pharmaceutical giant, has announced that the US Food and Drug Administration (FDA) has granted approval for Ocrevus Zunovo (ocrelizumab, hyaluronidase), marking a significant advancement in the treatment of multiple sclerosis (MS). This new formulation is the first and only twice-per-year treatment…
